Aligos Therapeutics, Inc.
ALGS
$5.23
-$1.25-19.29%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 629.00K | 1.27M | 1.06M | 986.00K | 2.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 629.00K | 1.27M | 1.06M | 986.00K | 2.68M |
| Cost of Revenue | 16.03M | 16.77M | 21.10M | 16.37M | 22.26M |
| Gross Profit | -15.40M | -15.51M | -20.04M | -15.38M | -19.58M |
| SG&A Expenses | 5.16M | 4.63M | 6.38M | 6.67M | 5.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.19M | 21.40M | 27.48M | 23.03M | 27.95M |
| Operating Income | -20.56M | -20.13M | -26.41M | -22.05M | -25.27M |
| Income Before Tax | -82.12M | -19.17M | 5.25M | -34.84M | -27.92M |
| Income Tax Expenses | 27.00K | 91.00K | 189.00K | 24.00K | -30.00K |
| Earnings from Continuing Operations | -82.15M | -19.26M | 5.06M | -34.86M | -27.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.15M | -19.26M | 5.06M | -34.86M | -27.89M |
| EBIT | -20.56M | -20.13M | -26.41M | -22.05M | -25.27M |
| EBITDA | -20.32M | -19.88M | -26.16M | -21.76M | -24.88M |
| EPS Basic | -13.08 | -3.07 | 0.81 | -5.58 | -5.50 |
| Normalized Basic EPS | -8.17 | -1.91 | 0.52 | -3.49 | -3.35 |
| EPS Diluted | -13.08 | -3.07 | 0.75 | -5.58 | -5.50 |
| Normalized Diluted EPS | -8.17 | -1.91 | 0.52 | -3.49 | -3.35 |
| Average Basic Shares Outstanding | 6.28M | 6.27M | 6.26M | 6.25M | 5.07M |
| Average Diluted Shares Outstanding | 6.28M | 6.27M | 6.27M | 6.25M | 5.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
